BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma
BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma
复制标题
DOI：
10.4149/neo_2017_419
复制
发表时间：
2017-01-01
期刊：
影响因子：
3
通讯作者：
Si, L.
中科院分区：
文献类型：
--
作者：
Bai, X.;Mao, L. L.;Si, L.
BRAF抑制剂在皮肤黑色素瘤中具有显著的临床疗效。然而，它们在肢端和粘膜黑色素瘤中的作用仍不清楚。审查了2011年1月至2016年3月期间住院并接受BRAF抑制剂治疗的转移性或不可切除的BRAF突变型肢端和粘膜黑色素瘤患者的记录。收集临床数据以确定PFS、ORR、DCR、OS和安全性。在接受BRAF抑制剂治疗的28例肢端和12例粘膜黑色素瘤患者中，中位PFS为3.6（95%CI 3.0-6.4）和4.4（95%CI 0.8-12.7）个月，中位OS为6.2（95%CI 6.1-12.1）和8.2（95%CI 6.6-19.9）个月;肢端和粘膜黑色素瘤的ORR分别为38.1%和20.0%，DCR分别为81.0%和70.0%。BRAF抑制剂耐受良好。最常见的不良反应（AE）为皮肤和血液学。3/4级AE相对罕见。总之，BRAF抑制剂在BRAF突变型肢端和粘膜黑色素瘤中具有可接受的疗效和良好的耐受性。
BRAF inhibitors substantially have impressive clinical efficacy in cutaneous melanoma. However, their role in acral and mucosal melanoma remains unclear. Records were reviewed of patients with metastatic or unresectable BRAF-mutant acral and mucosal melanoma hospitalized and administrated BRAF inhibitors during January 2011 and March 2016. Clinical data were collected to determine PFS, ORR, DCR, OS, and safety. Among 28 acral and 12 mucosal melanoma patients treated with BRAF inhibitors, median PFS were 3.6 (95%CI 3.0-6.4) and 4.4 (95%CI 0.8-12.7) months, median OS were 6.2 (95%CI 6.1-12.1) and 8.2 (95%CI 6.6-19.9) months; ORRs were 38.1% and 20.0%, DCRs were 81.0% and 70.0% in acral and mucosal melanoma, respectively. BRAF inhibitors were well tolerated. The most common adverse effects (AEs) were cutaneous and hematological. Grade 3/4 AEs were relatively rare. In conclusion, BRAF inhibitors have acceptable efficacy and good tolerance in BRAF mutant acral and mucosal melanoma.